Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2016-04-27 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2016-04-27 English
FORM 4 -
Director's Dealing
2016-04-27 English
FORM 4 -
Director's Dealing
2016-04-27 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, specifically reporting the departure of a senior officer, George B. Abercrombie, from his position as Senior Vice President, Chief Commercial Officer. The text explicitly mentions this is an Item 5.02 report, which relates to departure or election of directors or officers. There is no financial data, earnings information, or report publication mentioned. The content fits the category of Board/Management Information (MANG) as it announces a change in senior management.
2016-04-20 English
DEF 14A
Proxy Solicitation & Information Statement
2016-03-25 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on, instructions for voting, and other meeting logistics. The text explicitly identifies itself as a Proxy Statement and includes the Notice of Annual Meeting and proxy solicitation materials. It is not an Annual Report, Earnings Release, or any other financial report, but rather materials sent to shareholders to provide information and request votes for the meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the full proxy statement, not just an announcement or a brief notice.
2016-03-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.